Search results
Bristol Myers must face $6.4 billion lawsuit over delayed cancer drug
Reuters via Yahoo Finance· 2 years agoA U.S. judge on Friday refused to dismiss a $6.4 billion lawsuit accusing Bristol Myers Squibb Co of...
New York Judge Denies Bristol Myers Claim To Dismiss Lawsuit Over Delayed Cancer Drug Approval:...
Benzinga via Yahoo Finance· 2 years agoAccording to a Reuters report, U.S. District Judge Jesse Furman in Manhattan refused to dismiss a...
Bear of the Day: Ligand Pharmaceuticals (LGND)
Zacks via Yahoo Finance· 11 months agoLigand Pharmaceuticals (LGND) is a $1 billion operator of bio-pharmaceutical acquisitions and development. The San Diego company focuses on developing or...
Former Bristol Myers CEO tapped as Novartis’ next board chair
BioPharma Dive via Yahoo Finance· 1 month agoGiovanni Caforio, who left Bristol Myers in November after eight years as CEO, is set to succeed...
Pfizer is buying a cancer biotech in one of the biggest pharma deals in history
Quartz via Yahoo Finance· 1 year agoPharmaceutical giant Pfizer is buying Seagen, a biotech company making a novel type of cancer...
Is Bristol Myers Squibb a Top Dividend Stock?
Motley Fool· 1 year agoBristol Myers Squibb (BMS) (NYSE: BMY), a multinational pharmaceutical company, has all the hallmarks of a top-shelf dividend stock. The company has...
Amgen (AMGN) Wins Patent Appeal for Blockbuster Psoriasis Drug
Zacks via Yahoo Finance· 1 year agoThe Appeal Court's decision upholding the patents for Amgen's (AMGN) blockbuster psoriasis drug...
Fresh Blood: 3 Stocks Ready to Rally Under New CEOs
InvestorPlace via Yahoo Finance· 11 months agoIn recent years, S&P 500 companies with new chief executive officers (CEOs) have become a regular occurrence. That’s because CEOs are moving on more...
3 Stocks to Snag for Less Than Book Value
InvestorPlace via Yahoo Finance· 11 months agoThe move to share repurchases over the last few years has made the price-to-book ratio less reliable for finding hidden opportunities in stocks. How’s...
Biotech landlord Alexandria on research clusters and the sector’s recovery
BioPharma Dive via Yahoo Finance· 2 months agoJoel Marcus, the longtime head of Alexandria Real Estate Equities, sees few near-term challengers to...
